Avatar
Yahoo News source @yahoo.com · Sunnyvale, California 🇺🇸· Jan 19

#WomensHealth #Contraception #FDAApproval

Link Preview
www.yahoo.com
FDA expands use of Organon's contraception implant up to 5 years
Yahoo is using AI to generate takeaways from this article.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#DepressionTreatment #FDAApproval #Pharmaceuticals

Link Preview
www.benzinga.com
Why Is GH Research Stock Soaring Monday? - GH Research (NASDAQ:GHRS)
The U.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Biopharmaceuticals #LiverDisease #FDAApproval

Link Preview
www.benzinga.com
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - Altimmune (NASDAQ:ALT)
GAITHERSBURG, Md.
Avatar
NASDAQ Stock Market News source @nasdaq.com · New York City 🇺🇸· Jan 5

#MultipleSclerosis #FDAApproval #GenericDrugs

Link Preview
www.nasdaq.com
ScinoPharm Wins First FDA Approval With Glatiramer Acetate Injection For Multiple Sclerosis
(RTTNews) - ScinoPharm Taiwan (TWSE: 1789) today announced that the U.
Avatar
Benzinga News source @benzinga.com · Detroit 🇺🇸· Jan 5

#Type1Diabetes #Sanofi #FDAApproval

Link Preview
www.benzinga.com
Press Release: Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter Sanofi's Tzield accepted for priority review in the US for young children with stage 2 type 1 diabetes If approved, Tzield would be the first disease-modifying therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1DTzield slows disease progression by protecting the insulin-secreting beta cells of the pancreasThe priority review is based on interim results from the PETITE-T1D phase 4 study Paris, January 5, 2026.
Avatar
Barchart.com News source @barchart.com · United States 🇺🇸· Jan 5

#Pharmaceuticals #MultipleSclerosis #FDAApproval

Link Preview
www.barchart.com
ScinoPharm Secures U.S. FDA Approval for Glatiramer Acetate Injection for the Treatment of Multiple Sclerosis
All information and data in this article is solely for informational purposes.
Avatar
Seeking Alpha News source @seekingalpha.com · Jan 4

#Biotech #Pharmaceuticals #FDAApproval

Link Preview
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.